E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Hepatitis C Virus Infection |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019744 |
E.1.2 | Term | Hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008912 |
E.1.2 | Term | Chronic hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate the efficacy of treatment with SOF/VEL fixed dose combination (FDC) for 12 weeks in subjects with chronic HCV infection as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12) - To evaluate the safety and tolerability of treatment with SOF/VEL for 12 weeks |
|
E.2.2 | Secondary objectives of the trial |
- To determine the proportion of subjects who attain SVR at 4 and 24 weeks after cessation of treatment (SVR4 and SVR24) - To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of treatment - To evaluate the emergence of viral resistance to SOF and VEL during treatment and after cessation of treatment |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must meet all of the following inclusion criteria to be eligible for participation in this study. 1) Willing and able to provide written informed consent. 2) Male or female, age ≥ 18 years. 3) HCV RNA ≥ to 104 IU/mL at Screening. 4) HCV genotype 1, 2, 3, 4, 5, 6 assessed at Screening by the Central Laboratory. 5) Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy. 6) Classification as treatment naïve or treatment experienced. 10) Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in Appendix 4.
|
|
E.4 | Principal exclusion criteria |
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study. 1) Current or prior history of any of the following: a) Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. 2) Screening ECG with clinically significant abnormalities 3) Any of the following laboratory parameters at screening: a) ALT > 10 x the upper limit of normal (ULN) b) AST > 10 x ULN c) Direct bilirubin > 1.5 x ULN d) Platelets < 50,000/uL e) HbA1c > 8.5% f) Creatinine clearance (CLcr) < 60 mL /min as calculated by the Cockcroft-Gault equation g) Hemoglobin < 11 g/dL for female subjects; < 12 g/dL for male subjects. h) Albumin < 3 g/dL i) INR > 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR 4) Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A inhibitor
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints of this study are: - Primary efficacy endpoint is SVR12 in all enrolled subjects after 12 weeks of SOF/VEL treatment - Primary safety endpoint is Safety and tolerability after 12 weeks of SOF/VEL treatment and AE leading to drug discontinuation |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The safety and tolerability endpoints are evaluated during the course of treatment. The efficacy endpoint is evaluated 12 weeks after discontinuation of therapy. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints of this study are: - SVR4 and SVR24 in all enrolled subjects after 12 weeks of SOF/VEL treatment - Kinetics of HCV virus - Emergence of the viral resistance after 12 weeks of treatment and resistance associated variants |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The efficacy endpoints are evaluated 4 and 24 weeks after discontinuation of therapy. The other endpoints are evaluated during the course of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The date that the last subject has completed the protocol defined activities |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |